Rapid eradication of a bulky melanoma mass with one dose of immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

28 citing papers in PubMed.

1. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.Cancer immunology, immunotherapy : CII · 2016
   Trial
2. Therapeutic targeting of regulatory T cells in cancer.Trends in cancer · 2022
   Review
3. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
   Article
4. A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy.Frontiers in immunology · 2020
   Review
5. Clinical protein science in translational medicine targeting malignant melanoma.Cell biology and toxicology · 2019
   Article
6. Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
   Article
7. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
   Article
8. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Pharmacology & therapeutics · 2017
   Review
9. Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.Therapeutic advances in vaccines · 2017
   Article
10. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.Nature reviews. Drug discovery · 2017
    Review
11. Tumor lysis syndrome and metastatic melanoma.Medical oncology (Northwood, London, England) · 2016
    Article
12. Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.Protein & cell · 2016
    Review
13. A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis.International cancer conference journal · 2016
    Article
14. Roles of regulatory T cells in cancer immunity.International immunology · 2016
    Review
15. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Nature reviews. Clinical oncology · 2016
    Review
16. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.Journal of the National Comprehensive Cancer Network : JNCCN · 2016
    Article
17. HIV-specific CD8⁺ T cells and HIV eradication.The Journal of clinical investigation · 2016
    Review
18. Nrf2 Deficiency Promotes Melanoma Growth and Lung Metastasis.Reactive oxygen species (Apex, N.C.) · 2016
    Article
19. Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.Journal for immunotherapy of cancer · 2016
    Article
20. Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma.Journal of surgical oncology · 2015
    Article

Corrections and comments

• Erratum issued
  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy; Genetic Basis for Clinical Response to CTLA-4 Blockade; Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma; Nivolumab plus Ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma; Hepatotoxicity with Combination of Vemurafenib and Ipilimumab.2018

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as